证券代码：300246 证券简称：宝莱特 公告编号：2025-059 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1. 本次会议无否决或变更提案的情况； 股东出席的总体情况： 通过现场和网络投票的股东 161 人，代表股份 78,316,484 股，占公司有表决 权股份总数的 29.9369％。 其中：通过现场投票的股东 4 人，代表股份 77,319,334 股，占公司有表决权 1 证券代码：300246 证券简称：宝莱特 公告编号：2025-059 2. 本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 广东宝莱特医用科技股份有限公司（以下简称"公司"）2025 年第三次临时股 东会会议于 2025 年 9 月 2 日（星期二）14:30 在珠海市高新区永和路 9 号公司会 议室以现场会议及网络投票的方式召开。 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 2 日 9:15-9:25， ...

Group 1 - The company will pay interest on its convertible bonds, "宝莱转债," on September 4, 2025, for the period from September 4, 2024, to September 3, 2025, at a coupon rate of 2.5% [2][4] - Each holder of 10 bonds (with a face value of 1,000 RMB each) will receive 25.00 RMB in interest (including tax) [4][5] - The interest payment will be made through China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, to the registered bondholders as of the close of trading on September 3, 2025 [5][6] Group 2 - The interest income tax for individual bondholders is set at a rate of 20%, which will be withheld by the payment agents when distributing the interest [4][6] - Foreign institutional investors are exempt from corporate income tax and value-added tax on the interest income from these bonds until December 31, 2025 [6]

证券代码：300246 证券简称：宝莱特 公告编号：2025-058 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于宝莱转债 2025 年付息的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"宝莱转债"（债券代码：123065）将于 2025 年 9 月 4 日支付第五年利息， 每 10 张"宝莱转债"（面值 1,000 元）利息为 25.00 元（含税）。 8、下一付息期起息日：2025 年 9 月 4 日 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2020 年 9 月 4 日 向不特定对象发行的可转换公司债券将于 2025 年 9 月 4 日支付 2024 年 9 月 4 日至 2025 年 9 月 3 日的利息。根据公司《创业板向不特定对象发行可转换公司 债券募集说明书》（以下简称"《募集说明书》"）有关条款的规定，现将本次付 息有关事项公布如下： 一、可转债基本情况 债券代码：123065 债券简称：宝莱转债 2、债权登记日：2025 年 9 月 3 日 3、除息日：2025 年 9 月 ...

Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. recently engaged in in-depth discussions with three institutions regarding its business, performance, and new products [1] Group 1: Company Overview - Baolait has been focused on the research, production, and sales of medical devices since its establishment in 1993, being one of the earliest domestic manufacturers of medical monitors [3] - The company has received several accolades, including being recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [3] - Its monitoring equipment is utilized in thousands of medical institutions, with a diverse product range in life information and support, as well as a comprehensive layout in the renal medical field [3] Group 2: Performance Summary - In the first half of 2025, Baolait reported an operating income of 523.44 million yuan, a year-on-year decrease of 2.43%, while net profit reached 1.31 million yuan, a significant increase of 152.22% [4] - Total assets amounted to 2.41 billion yuan, down 3.66% from the beginning of the period, and shareholders' equity was 1.22 billion yuan, up 0.25% [4] - The health monitoring segment saw revenues of 111.95 million yuan, down 16.01%, while the blood purification segment reported revenues of 405.70 million yuan, an increase of 1.79% [4] Group 3: New Products and Market Strategy - Baolait has launched new products such as the peritoneal dialysis machine and showcased the visual laryngoscope and enteral nutrition pump at CMEF in the first half of 2025 [4] - The "old-for-new" policy is expected to boost demand for monitoring devices, particularly benefiting mid-to-high-end products, while also facilitating equipment upgrades in the blood purification business [4] - The company has begun expanding its overseas sales of blood purification products, with overseas revenue growing by 121.29% in the first half of 2025 [4] Group 4: Future Focus - In 2025, Baolait aims to concentrate on its two main businesses, leveraging opportunities in new medical infrastructure, and developing high-margin intelligent IoT products [4] - The company plans to optimize its blood purification consumables supply chain and operational efficiency to enhance product penetration [4]

Company Overview - Founded in 1993, Baolait Medical Technology Co., Ltd. specializes in the R&D, production, and sales of medical devices, particularly monitoring equipment [1] - Recognized as a national industrialization base for multi-parameter monitors and a national champion in manufacturing [1] - Products are widely used in thousands of medical institutions across various settings, including general wards, emergency rooms, ICUs, and home healthcare [1][2] Financial Performance - In H1 2025, the company reported revenue of CNY 523.44 million, a decrease of 2.43% year-on-year [3] - Net profit attributable to shareholders was CNY 1.31 million, an increase of 152.22% year-on-year [3] - Total assets at the end of the reporting period were CNY 2.41 billion, down 3.66% from the beginning of the year [3] - The health monitoring segment saw sales of CNY 111.95 million, down 16.01%, while the blood purification segment reported sales of CNY 405.70 million, up 1.79% [3] Product Development - Recent product launches include peritoneal dialysis machines, S-series infusion pumps, and remote monitoring devices [4][5] - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF in H1 2025 [4][5] Market Impact and Policies - The "old-for-new" policy positively impacts the monitoring equipment business by increasing demand for updated devices [6] - The company is positioned to benefit from the expansion of grassroots medical institutions and the upgrade of blood purification centers [6] International Sales - Blood purification products have begun to penetrate overseas markets, with a 121.29% increase in overseas revenue in H1 2025 [7] Competitive Advantages - The D800 series of blood dialysis devices feature integrated monitoring capabilities and IoT systems, enhancing operational efficiency and patient care [8][9] - The D800Plus model is the first domestic three-pump device capable of mixed dilution dialysis, improving treatment outcomes [9] Regulatory Developments - New policies from the National Medical Insurance Administration include monitoring parameters in dialysis pricing, which aligns with the capabilities of the D800 series [10] Patient Demographics - As of 2024, the number of patients undergoing hemodialysis is approximately 1.027 million, maintaining a compound annual growth rate of about 12% over the past decade [11] - Patients typically require dialysis treatment three times a week [11] Strategic Focus for 2025 - The company aims to focus on high-end, intelligent, and IoT-enabled products while enhancing the penetration of high-margin products in critical care and anesthesia [12] - Plans to leverage national production bases and embrace centralized procurement policies to improve operational efficiency and product availability [12][13]

Group 1 - The company has completed the industrial and commercial change registration, increasing its registered capital to 264.5759 million yuan [2] - The company's business scope has been expanded to include technical services and technical development [2] - The company's name has been changed to Guangdong Baolait Medical Technology Co., Ltd., with Yan Jinyuan as the legal representative [2]

Core Viewpoint - The financial performance of Baolait (300246) shows a mixed trend with a slight decrease in revenue but a significant increase in net profit, indicating potential areas for investment analysis [1] Financial Performance - As of the latest mid-year report, Baolait reported total revenue of 523 million yuan, a year-on-year decrease of 2.43% [1] - The net profit attributable to shareholders was 1.31 million yuan, reflecting a year-on-year increase of 152.22% [1] - The non-recurring net profit was 16.47 million yuan, which represents a year-on-year decrease of 6.80% [1] - The current ratio is 2.188, the quick ratio is 1.724, and the debt-to-asset ratio stands at 46.18% [1] Market Activity - As of August 25, 2025, Baolait's stock closed at 9.48 yuan, with a slight increase of 0.32% [1] - The trading volume was 109,200 hands, with a total transaction amount of 104 million yuan [1] - There was a net outflow of main funds amounting to 10.00 million yuan, accounting for 9.66% of the transaction amount [1] - Large orders saw a net outflow of 7.89 million yuan, while small orders experienced a net inflow of 2.02 million yuan [1] Company Background - Baolait Medical Technology Co., Ltd. was established in 1993 and is located in Zhuhai City, focusing on research and experimental development [2] - The company has invested in 21 enterprises and participated in 977 bidding projects [2] - Baolait holds 58 trademark registrations and 330 patents, along with 179 administrative licenses [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-057 债券代码：123065 债券简称：宝莱转债 统一社会信用代码：914404006175020946 商事主体类型：其他股份有限公司（上市） 法定代表人：燕金元 成立日期：1993 年 06 月 28 日 广东宝莱特医用科技股份有限公司 关于公司完成工商变更登记的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、概述 广东宝莱特医用科技股份有限公司（以下简称"公司"）分别于 2025 年 7 月 16 日召开的第八届董事会第二十五次会议、2025 年 8 月 1 日召开的 2025 年第二 次临时股东大会，审议通过了《关于增加公司注册资本及修订〈公司章程〉的议 案》。具体内容详见公司于 2025 年 7 月 17 日于指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于增加注册资本及修订〈公司章程〉的 公告》（公告编号 2025-042）。 公司于近日完成了上述事项的变更登记和备案手续，并取得了珠海市市场监 督管理局发出的《登记通知书》。变更后具体登 ...

Group 1 - Baolite has experienced a decline for four consecutive trading days, with a cumulative drop of -5.33% [1] - Guangdong Baolite Medical Technology Co., Ltd. is a national high-tech enterprise engaged in the research, production, and sales of medical devices, covering three main business areas: life information and support, nephrology, and health care [1] - Jin Yuan Shun An Fund's Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is among Baolite's top ten shareholders, having increased its holdings in the second quarter of this year [1] Group 2 - The Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund has achieved a year-to-date return of 31.54%, ranking 320 out of 2279 in its category [2] - The fund's performance over various periods includes a 2.81% increase over the past week, 3.89% over the past month, and 15.87% over the past three months [2] - The fund manager, Miao Weibin, has a background in economics from Fudan University and has held various positions in asset management prior to joining Jin Yuan Shun An Fund in October 2016 [3][4]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Baolait Medical Technology Co., Ltd. as of August 19, 2025, indicating a decline in stock price and mixed financial results [1][3] - As of the latest report, Baolait's total revenue for the first half of 2025 was 523 million yuan, representing a year-on-year decrease of 2.43%, while net profit attributable to shareholders was 1.3134 million yuan, showing a significant year-on-year increase of 152.22% [1] - The company's liquidity ratios are reported as a current ratio of 2.188 and a quick ratio of 1.724, with a debt-to-asset ratio of 46.18%, indicating a relatively stable financial position [1] Group 2 - Baolait has made investments in 21 companies and has participated in 970 bidding projects, showcasing its active engagement in the market [2] - The company holds 58 trademark registrations and 330 patents, reflecting its focus on intellectual property and innovation [2] - Additionally, Baolait possesses 179 administrative licenses, indicating compliance with regulatory requirements and operational capabilities [2]